Estrogen-Containing Oral Contraceptives has 12 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Anastrozole, Anastrozole Tablets, Lamotrigine. Patients taking Estrogen-Containing Oral Contraceptives should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 12
- Contraindicated
- 2
- Major
- 1
- Moderate
- 9
Contraindicated (2)
- Estrogen-Containing Oral Contraceptives + Anastrozole— Estrogen-containing therapies should not be used with anastrozole as they may diminish its pharmacological action.
- Estrogen-Containing Oral Contraceptives + Anastrozole Tablets— Estrogen-containing therapies should not be used with anastrozole as they may diminish its pharmacological action.
Major (1)
- Estrogen-Containing Oral Contraceptives + Lamotrigine— Estrogen-containing oral contraceptives decrease lamotrigine concentrations by approximately 50%, requiring dose adjustm…
Moderate (9)
- Estrogen-Containing Oral Contraceptives + Divalproex Sodium— May affect valproate clearance. Monitoring of valproate concentrations is recommended.
- Estrogen-Containing Oral Contraceptives + Divalproex Sodium Er— May increase the clearance of valproate, decreasing valproate concentration and potentially increasing seizure frequency…
- Estrogen-Containing Oral Contraceptives + Duloxetine D/R— May increase clearance of valproate, resulting in decreased valproate concentration and potentially increased seizure fr…
- Estrogen-Containing Oral Contraceptives + Lamotrigine Chewable Dispersible— Decreased lamotrigine levels approximately 50%. Decrease in levonorgestrel component by 19%.
- Estrogen-Containing Oral Contraceptives + Levothyroxine Sodium— May increase serum thyroxine-binding globulin concentration, resulting in initial transient increase in FT4 followed by …
- Estrogen-Containing Oral Contraceptives + Liothyronine Sodium— May increase serum thyroxine-binding globulin concentration, altering T3 serum transport. Closely monitor thyroid hormon…
- Estrogen-Containing Oral Contraceptives + Topiramate— Decreased contraceptive efficacy and increased breakthrough bleeding, especially at doses greater than 200 mg/day.
- Estrogen-Containing Oral Contraceptives + Valproate Sodium— Estrogen-containing hormonal contraceptives may affect valproate pharmacokinetics. Monitoring of valproate concentration…
- Estrogen-Containing Oral Contraceptives + Valproic Acid— May affect valproate clearance. Monitoring of valproate concentrations recommended.